Shiyao Innovation announced that the holding subsidiary Shiyao Group Jushi Biopharmaceutical Co., Ltd. has recently launched a randomized, multi-center, open-label clinical trial evaluating SYS6043 compared the chemotherapies selected by researchers for platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer participants.

Shiyao Innovation announced that the holding subsidiary Shiyao Group Jushi Biopharmaceutical Co., Ltd. has recently launched a randomized, multi-center, open-label clinical trial evaluating SYS6043 compared the chemotherapies selected by researchers for platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer participants.